Skip to content
Inciteful Med

Treatment Options and Fetal Interventions for NIHF

Last updated:

Treatment for non-immune hydrops fetalis (NIHF) depends entirely on its underlying cause. Care options range from in-utero interventions like blood transfusions or fluid-draining shunts to maternal medications, close monitoring, and specialized NICU support after birth.

Key Takeaways

  • • Treatment for non-immune hydrops fetalis is highly individualized and depends entirely on identifying the specific underlying cause.
  • • In-utero interventions, such as intrauterine transfusions and thoracoamniotic shunts, can successfully treat fetal anemia and severe fluid buildup in the chest.
  • • Mothers can take specific anti-arrhythmic medications that cross the placenta to correct fetal heart rhythm problems causing the hydrops.
  • • In certain isolated cases, non-immune hydrops fetalis may resolve spontaneously on its own with close expectant management and ultrasound monitoring.
  • • Babies born with NIHF generally require specialized breathing and fluid support in the NICU, alongside condition-specific therapies.

Treatment for non-immune hydrops fetalis (NIHF) is not “one size fits all.” Because hydrops is a symptom of an underlying condition, the treatment plan depends entirely on identifying that specific cause [1]. While some cases require intensive intervention, others may be managed with close monitoring.

In-Utero Fetal Interventions

In some scenarios, doctors can treat the baby while they are still in the womb. These procedures are typically performed at specialized fetal care centers.

1. Intrauterine Transfusion (IUT)

If the hydrops is caused by severe fetal anemia (often from an infection like Parvovirus B19 or a blood disorder), a doctor can perform a blood transfusion through the umbilical cord [2][3].

  • Success Rates: In experienced centers, the survival rate for babies treated with IUT for Parvovirus-related anemia is approximately 67% to 85% [2][4].
  • The Goal: The transfusion provides the baby with healthy red blood cells, allowing the heart to work more efficiently and the fluid to resolve [5].

2. Thoracoamniotic Shunts

When fluid builds up heavily in the baby’s chest (pleural effusion), it can compress the lungs and shift the heart [6]. A surgeon can place a small tube (shunt) to drain this fluid into the amniotic sac [7].

  • Impact: Shunting has been shown to improve survival (from roughly 32% without therapy to over 58% with it) and can help the baby reach a later delivery date [8][9].
  • Recovery: Babies treated with shunts often spend less time in the Neonatal Intensive Care Unit (NICU) [9].

3. Anti-Arrhythmic Medications

If an abnormal heart rhythm (arrhythmia) is causing the fluid buildup, the mother can take medications like Flecainide or Sotalol [10]. These medications cross the placenta to reach the baby and help convert the heart back to a normal rhythm [11].

  • Effectiveness: When the heart rhythm returns to normal, the hydrops can resolve completely in many cases [12][13].

Expectant Management and Spontaneous Resolution

In certain cases, especially when the NIHF is “isolated” (meaning no other anomalies are found) or the cause is unknown, doctors may recommend expectant management—which means monitoring the pregnancy very closely with frequent ultrasounds without immediate intervention [14].

  • Spontaneous Resolution: Remarkably, in a subset of cases known as isolated NIHF, the fluid can sometimes resolve completely on its own [14]. When the fluid resolves before birth, the chance of the baby coming home healthy is extremely high, up to 98% [14].

Postnatal and Targeted Therapies

Some conditions that cause NIHF require specialized care immediately after the baby is born.

  • Metabolic Disorders: For babies with MPS VII (Sly Syndrome), a treatment called Enzyme Replacement Therapy (ERT) can be started shortly after birth [15][16]. This therapy helps replace the missing enzyme and can reduce the severity of the disease [17]. Additionally, in-utero ERT is now emerging as a treatment in clinical trials at highly specialized centers [15].
  • NICU Care: Regardless of the cause, most babies with a history of NIHF will need specialized support in the NICU to help with breathing and fluid management after delivery [18][19].

Every case of NIHF is unique. Your Maternal-Fetal Medicine specialist will work with a team of cardiologists, geneticists, and neonatologists to determine which of these paths—intervention, expectant management, or postnatal planning—is right for your family [1].

Return to Introduction

Frequently Asked Questions

Can non-immune hydrops fetalis be treated before birth?
Yes, if the underlying cause is identified early, specialized fetal care centers can perform in-utero procedures. These may include intrauterine blood transfusions for severe anemia or placing a shunt to drain excess fluid from the baby's chest.
What does a thoracoamniotic shunt do?
A thoracoamniotic shunt is a small tube placed by a surgeon to drain excess fluid from the baby's chest into the amniotic sac. This procedure relieves pressure on the baby's lungs and heart, improving survival rates and potentially allowing the pregnancy to progress further.
How are fetal heart rhythm issues treated during pregnancy?
If an abnormal heart rhythm is causing the fetal fluid buildup, the mother may be prescribed anti-arrhythmic medications like Flecainide or Sotalol. These medicines cross the placenta to reach the baby and help restore a normal heart rhythm, which can often resolve the hydrops.
Can non-immune hydrops fetalis go away on its own?
In some cases, particularly when the hydrops is isolated and no other anomalies are found, the fluid can resolve completely on its own. Doctors will use expectant management, involving very close monitoring with frequent ultrasounds, to watch the baby's progress.
What kind of care will my baby need immediately after birth?
Most babies with a history of NIHF will require specialized care in the Neonatal Intensive Care Unit (NICU) to assist with breathing and fluid management. Depending on the exact cause, babies may also receive targeted treatments like enzyme replacement therapy immediately after delivery.

Questions for Your Doctor

  • • Based on the current cause of the hydrops, is my baby a candidate for any in-utero interventions, such as a shunt or a transfusion?
  • • If we are considering a thoracoamniotic shunt, what are the specific risks of the procedure and the likelihood of improving the outcome?
  • • For a heart rhythm issue, which anti-arrhythmic medication (like Flecainide or Sotalol) do you recommend, and how will I be monitored for side effects?
  • • If a genetic or metabolic cause is suspected, are there any targeted treatments we should plan for immediately after birth?
  • • If we choose 'expectant management,' how often will we need ultrasounds to monitor the fluid levels?

Questions for You

  • • How do I feel about the risks of an invasive fetal procedure versus the potential benefits for my baby?
  • • Do I have a support system in place if we need to travel to a specialized center for fetal therapy?
  • • What are my primary goals for my baby's care—focusing on all possible interventions, or focusing on comfort?
  • • Am I experiencing any symptoms like sudden swelling or high blood pressure that I need to report to my doctor immediately?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Nonimmune hydrops fetalis: Genetic analysis and clinical outcome.

    Deng Q, Fu F, Yu Q, et al.

    Prenatal diagnosis 2020; (40(7)):803-812 doi:10.1002/pd.5691.

    PMID: 32267001
  2. 2

    Parvovirus b19 infection in pregnancy - A review.

    Gigi CE, Anumba DOC

    European journal of obstetrics, gynecology, and reproductive biology 2021; (264()):358-362 doi:10.1016/j.ejogrb.2021.07.046.

    PMID: 34391051
  3. 3

    Intrauterine transfusion: Best practices, techniques, and evolving trends.

    Devlieger R, Vergote S, Van den Eede E, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2026; (104()):102686 doi:10.1016/j.bpobgyn.2025.102686.

    PMID: 41289715
  4. 4

    Intrauterine transfusion in 103 fetuses with severe anemia caused by parvovirus infection. A multicenter retrospective study.

    Kosian P, Hellmund A, Geipel A, et al.

    Archives of gynecology and obstetrics 2023; (308(1)):117-125 doi:10.1007/s00404-022-06712-z.

    PMID: 35916962
  5. 5

    Ten years' experience in prenatal diagnosis of α-thalassemia in a municipal hospital and retrospective analysis of ultrasonic abnormalities.

    Li H, Wang J, Wang D, et al.

    International journal of hematology 2023; (118(3)):355-363 doi:10.1007/s12185-023-03643-6.

    PMID: 37477864
  6. 6

    Outcome and etiology of fetal pleural effusion, fetal ascites and hydrops fetalis after fetal intervention: retrospective observational cohort from a single institution.

    Wu WJ, Ma GC, Chang TY, et al.

    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2024; (63(4)):536-543 doi:10.1002/uog.27501.

    PMID: 37767652
  7. 7

    National registry of thoracoamniotic shunting using a double-basket catheter: A post-marketing surveillance registry of 295 patients with fetal hydrothorax.

    Takahashi Y, Ishii K, Ishikawa H, et al.

    Prenatal diagnosis 2024; (44(8)):971-978 doi:10.1002/pd.6587.

    PMID: 38743216
  8. 8

    Prenatal Management and Perinatal Outcome in a Large Series of Hydrops Fetalis.

    Sebastián de Lucas LM, Ordás Álvarez P, de Castro Marzo L, et al.

    Fetal diagnosis and therapy 2024; (51(4)):335-342 doi:10.1159/000538857.

    PMID: 38643756
  9. 9

    Antenatal shunting and outcomes in fetuses with non-immune hydrops fetalis.

    Fragala V, Sabale S, Ashoor G, et al.

    Journal of perinatal medicine 2025; doi:10.1515/jpm-2025-0198.

    PMID: 40851234
  10. 10

    Transplacental treatment of fetal tachycardia: A systematic review and meta-analysis.

    Hill GD, Kovach JR, Saudek DE, et al.

    Prenatal diagnosis 2017; (37(11)):1076-1083 doi:10.1002/pd.5144.

    PMID: 28833310
  11. 11

    Fetal arrhythmias: diagnosis and treatment.

    Yuan SM

    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2020; (33(15)):2671-2678 doi:10.1080/14767058.2018.1555804.

    PMID: 30879368
  12. 12

    Nonimmune hydrops fetalis management from the perspective of fetal cardiologists: A single tertiary center experience from Egypt.

    Rakha S, Elmarsafawy H

    Journal of neonatal-perinatal medicine 2021; (14(2)):237-244 doi:10.3233/NPM-200491.

    PMID: 33074198
  13. 13

    Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.

    Tunca Sahin G, Beattie RB, Uzun O

    Cardiology in the young 2022; (32(7)):1077-1084 doi:10.1017/S104795112100367X.

    PMID: 34551832
  14. 14

    Isolated non-immune hydrops fetalis: an observational study on complete spontaneous resolution, perinatal outcome, and long-term follow-up.

    Neveling S, Knippel AJ, Kozlowski P

    Archives of gynecology and obstetrics 2023; (308(2)):487-497 doi:10.1007/s00404-022-06731-w.

    PMID: 35994111
  15. 15

    Prenatal diagnosis of mucopolysaccharidosis type VII facilitating treatment in neonatal period.

    Chandler NJ, Ramachandran V, Beesley C, et al.

    Prenatal diagnosis 2023; (43(12)):1567-1569 doi:10.1002/pd.6455.

    PMID: 37964423
  16. 16

    Vestronidase Alfa: A Review in Mucopolysaccharidosis VII.

    McCafferty EH, Scott LJ

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2019; (33(2)):233-240 doi:10.1007/s40259-019-00344-7.

    PMID: 30848434
  17. 17

    Open-label phase 1/2 study of vestronidase alfa for mucopolysaccharidosis VII.

    Jones S, Coker M, López AG, et al.

    Molecular genetics and metabolism reports 2021; (28()):100774 doi:10.1016/j.ymgmr.2021.100774.

    PMID: 34136357
  18. 18

    Neonatal management and outcome after thoracoamniotic shunt placement for fetal hydrothorax.

    Witlox RSGM, Klumper FJCM, Te Pas AB, et al.

    Archives of disease in childhood. Fetal and neonatal edition 2018; (103(3)):F245-F249 doi:10.1136/archdischild-2016-311265.

    PMID: 28780497
  19. 19

    Long-Term Outcomes After Thoracoamniotic Shunt for Pleural Effusions With Secondary Hydrops.

    Chon AH, Chmait HR, Korst LM, et al.

    The Journal of surgical research 2019; (233()):304-309 doi:10.1016/j.jss.2018.08.022.

    PMID: 30502263

This page provides educational information about fetal interventions and treatment options for non-immune hydrops fetalis. Always consult your maternal-fetal medicine specialist to determine the safest and most appropriate care plan for your pregnancy.

Stay up to date

Get notified when new research about Non-immune hydrops fetalis is published.

No spam. Unsubscribe anytime.